GlaxoSmithKline unveiled its 2026 financial forecast on Wednesday, anticipating a deceleration in sales growth. This marks the first time new CEO Luke Miels has presented performance expectations, as the pharmaceutical giant shifts its focus toward expanding its research pipeline to address the impending patent expiration of its blockbuster HIV treatments.
At constant exchange rates, GlaxoSmithKline projects revenue growth between 3% and 5% for 2026, a notable decrease from the 7% growth anticipated for 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments